Compare TALK & KALV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TALK | KALV |
|---|---|---|
| Founded | 2012 | N/A |
| Country | United States | United States |
| Employees | 521 | N/A |
| Industry | Medical/Nursing Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 788.5M | 757.7M |
| IPO Year | N/A | 2014 |
| Metric | TALK | KALV |
|---|---|---|
| Price | $5.13 | $17.02 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 5 |
| Target Price | $6.42 | ★ $30.00 |
| AVG Volume (30 Days) | ★ 5.8M | 761.7K |
| Earning Date | 05-05-2026 | 05-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $50,000,000.00 |
| Revenue This Year | $26.02 | N/A |
| Revenue Next Year | $21.24 | N/A |
| P/E Ratio | $155.55 | ★ N/A |
| Revenue Growth | N/A | ★ 495.66 |
| 52 Week Low | $2.22 | $9.83 |
| 52 Week High | $5.19 | $19.00 |
| Indicator | TALK | KALV |
|---|---|---|
| Relative Strength Index (RSI) | 66.17 | 56.35 |
| Support Level | $4.59 | $14.59 |
| Resistance Level | $5.19 | $17.30 |
| Average True Range (ATR) | 0.09 | 1.10 |
| MACD | -0.02 | -0.04 |
| Stochastic Oscillator | 90.02 | 57.48 |
Talkspace Inc is a behavioral healthcare company offering access to licensed therapists, psychologists, and psychiatrists through its technology platform. It serves clients including health plans, enterprises, and individual subscribers. Therapists address various mental health conditions, while psychiatrists cater to a higher acuity demographic. Revenue stems from payor and direct-to-enterprise clients, with contracts lasting one to three years. The majority of the Company's operations and revenues are based in the United States.
KalVista Pharmaceuticals Inc is a pharmaceutical company developing and delivering oral therapies for individuals affected by rare diseases with unmet needs. The company applies its knowledge in the kallikrein-kinin system (KKS) and oral drug discovery to develop small-molecule protease inhibitor medicines to address the needs of patients with diseases driven by plasma kallikrein and Factor XIIa. Its FDA-approved product EKTERLY (sebetralstat) is a novel, orally delivered, small-molecule plasma kallikrein inhibitor for the treatment of acute attacks of hereditary angioedema (HAE) in adult and pediatric patients aged twelve years and older.